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Assessment of Environmental
Carcinogen Risks in Terms of
Life Shortening
by Roy E. Albert* and Bernard Altshuler*
An approach is presented to the assessment of carcinogen risks in which the dominant
effect of carcinogen exposure is life shortening and the impact falls both on those in-
dividuals who would have gotten cancer without the carcinogen exposure as well as the
new cancer cases. This analysis is based on the interaction ofage-specific tumor incidence
rates and population survival in terms of age-specific mortality rates without the induced
risk from carcinogen exposure. The analysis yields estimates for lifetime probability of
developing cancer, average lifespan lost by the entire population, the average age of
cancer occurrence, and the average lifespan loss of cancer cases. The approach utilizes the
animal response data to assign, to the existing human cancer occurrence, an equivalent
dose of the same carcinogen which is under consideration in terms of risk evaluation. The
approach has the advantages of keying the estimates of carcinogen risks to those which
already exist in the environment, avoiding large extrapolations from animal data, and en-
compassing the variability in susceptibility and carcinogen exposure in humans.
Carcinogens can pollute the environment from
technological processes that are too important to
abandon, as for example, the combustion of fossil
and nuclear fuels for production of electricity.
Hence, it is necessary to estimate the magnitude of
cancer risks from environmental contamination as
an essential part of the process of weighing the
costs of controlling the release of carcinogens
against the consequences of deleterious health
effects and thus to make a rational choice between
alternative technological processes that achieve the
same ends.
The assessment of cancer risks from exposure to
known environmental carcinogens is an ex-
ceedingly difficult problem. Carcinogen exposures
will never be tolerated unless they are expected to
cause negligible increases in the existing burden of
cancer; unless there is a grave miscalculation in the
formulation of exposure limits, the actual risks
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could never be feasibly measured in humans and
certainly not in experimental animals. There are
additional uncertainties associated with differen-
tial sensitivity among humans and between
humans and test animals.
In principle, the only feasible basis for risk ex-
trapolations to very low levels of carcinogen ex-
posure is to develop a sound understanding in
animals ofthe component processes that determine
the dynamics of tumor formation and thereby
establish the general principles for making risk ex-
trapolations. It is also necessary to use
epidemiologic data on human cancer in response to
defined levelsofexposureinordertoequatethe rela-
tive sensitivities of human and animal for particu-
lar target organs and carcinogens. The conven-
tional method of assessing carcinogen hazards is
done by relating the level of dose to cancer inci-
dence. This implies that the extra cancer cases bear
the full effect of the carcinogen exposure and the
rest of the population suffers no ill effects. No at-
tention is paid to the age at which new cancer cases
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cinogen exposure could affect individuals who were
going to get cancer from other causes. The shape of
the dose-incidence curve used for extrapolations is
arbitrary as for example in the case ofthe Mantel-
Bryan approach which uses a log-normal
dose-response curve with a slope of one probit per
log dose (1). The thrust of this paper is that the
temporal patterns of mortality-corrected tumor in-
cidence should be used as the primary basis for
characterizing tumor responses from chronic car-
cinogen exposure since they are more directly rel-
ated to the time-dependent processes of neoplastic
cell transformation and growth of transformed
cells into tumors. The incidence and age at which
tumors form depend on the interaction ofthe tem-
poral tumor response patterns with population sur-
vival. This approach provides a more complete
characterization of carcinogen risks since the
effects are defined not only in terms of the excess
cancer incidence but also in terms of life shorten-
ing. Furthermore, the approach provides a way to
link the responses observed in test animals to that
already occurring in the same target organ in
humans and to circumvent the need for very large
extrapolations.
Strong evidence exists for a simple and
systematic relationship between the magnitude of
chronic life-time carcinogen exposure and the tem-
poral behavior of tumor incidence when corrected
for intercurrent mortality by conventional life-ta-
ble techniques. The early work by Blum on the in-
duction of skin cancer in the mouse by ultraviolet
radiation (2) and the later studies ofDruckrey with
various chemical carcinogens on a variety oftarget
organs (3) gave a mathematical formulation to the
common experience that the higher the level ofcar-
cinogen exposure the earlier the appearance of
tumors. These investigators showed that at a given
dose level, the cumulative incidence of tumors can
be represented by a log-normal distribution oftime
to tumor occurrence. Thus, the overall response
can be expressed in terms of the median time t for
tumor formation. The geometric standard
deviation o-Tg of the cumulative incidence provides
a measure of the temporal dispersion of the in-
dividual response times, i.e., the larger the
geometric standard deviation the more
heterogenous the response.
The relationship between the daily dose of car-
cinogend and the median time oftumor induction t
wasdtn = c, wheren and c are constants for a par-
ticular carcinogen and test system and the stan-
dard deviation (rg was insensitive to dose rate. As
shown elsewhere, the interaction ofthe log-normal
tumor incidence curve with the population survival
curve yields the cancer incidence, the average age
at which cancer develops, and the average amount
oflife lost bythe individuals developing cancer and
the amount of life lost averaged over the whole
population; the values ofn and o- have important
effects on the dose-response relafionships (4).
The above formulation implies that, at a given
dose level of carcinogen, every exposed individual
would develop cancer if he lived long enough. The
individuals that actually develop tumors are the
more susceptible members of the exposed popula-
tion; those that do not develop cancer are simply
less susceptible and die from extraneous causes
before they have a chance to develop cancer. The
contrast between the effects of higher and lower
carcinogen exposure levels is that the time oftumor
occurrence is shortened by the higher dose level in
all exposed individuals by the same proportion.
Thus, the susceptibles develop cancers earlier than
the less susceptibles at the lower exposure, and the
additional cancer cases occur because they now die
before other causes instead of afterward (in princi-
ple).
The applicability of dtn = c formulation to
human cancer is illustrated by the comparison of
stomach cancer in the U.S., Germany, and Japan
(5, 6). In all three areas, the cumulative mortality-
corrected incidence is log-normal with the same (rg
of 1.5. It is a reasonable supposition that dietary
factors are responsible for the differences in cancer
experiences in the three countries. The parallel log-
normal cumulative incidence curves support the
notion that incremental carcinogen exposure shor-
tens cancer development by a constant factor in the
entire population. On the assumption that n = 2,
the equivalent carcinogen exposure is 30% higher
in Germany and twice as high in Japan relative to
New York State. The large value of the geometric
standard deviation for stomach cancer in all three
countries (o- =1.5) suggests the existence ofa con-
siderable heferogeneity in the combined effects of
susceptibility and carcinogen dose.
The epidemiological data on stomach cancer il-
lustrates the generally accepted notion that much
of the current cancer experience in humans is due
to exposure to environmental carcinogens. It
follows that the impact of additional carcinogen
exposure should be described in terms of its in-
teraction with the existing cancer experience and
presumed carcinogen exposure. The biggest impact
that a small additional carcinogen exposure could
have on a population (that is already substantially
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ditional and existing carcinogens were the same
agents. This would shift the entire log-normal
response curve to an earlier age. By contrast, ifthe
actions were entirely independent, the small addi-
tional carcinogen exposure would have its own log-
normal incidence curve occurring at a later time
than that of the existing carcinogen exposure. The
summated effects of the two log-normal curves
would result in a deformed log-normal curve with
tumor development foreshortened only at the more
advanced ages.
A simple and conservative approach for estimat-
ing cancer risks could involve the use of the tumor
response data in test animals (for the particular
carcinogen whose risk is under consideration) to
assign an equivalent carcinogen dose do to the ex-
isting cancer experience in the human population
to be exposed. Thedo dose is thus one that provides
in animals a comparable temporal response to that
currently experienced by humans when the two
species are normalized for differences in life span
and under the assumption ofequal average suscep-
tibility in humans and the test animals. The impact
of an additional carcinogen dose d is evaluated in
humans in terms ofthe (do+d)tn=c formulation.
To illustrate the application of animal data to
the assignment of an equivalent carcinogen dosedo
to human cancer and the subsequent estimation of
risks, let us suppose that we are concerned about
the risks from the carcinogen diethylnitrosamine
(DENA) which is assumed to produce only primary
liver cancer in humans. A log-normal temporal
response for liver tumors over a wide range of dose
rates of DENA with n=2.2 has been reported by
[)ruckrey for an inbred strain of rats (3). The
cumulative incidence of primary liver cancer
reported by the Connecticut State Tumor Registry
for males in 1962-1964 (6) is log-normal with a o0g
of 1.7 and an extrapolated median time t of 350 yr.
For purposes of illustration, it is assumed that 1 yr
of human life span is equal to 1.52 weeks of life-
span in rats. The median time t of 350 yr corres-
ponds to 535 weeks in rats. The plot oflog d versus
logt for the DENA response ofrats is linear and ex-
trapolates to a dose of about 2 ptg/kg-day at 535
weeks which is taken to be the equivalent dose do
for the background primary liver cancer experience
in men. Computer calculations have been done for
normalized tumor responses covering a range of
values ofn and 0-g to obtain values for incidence,
average age of cancer occurrence and the average
amount of life span lost by cancer cases (4). In
these calculations, d was normalized to unity for t
equal to the 62-yr mean life span of humans. It is
assumed that humans exposed to DENA will show
the same n value as that observed in rats, i.e., n =
2.2, but org' which is a measure of heterogeneity of
response, is taken to be that for the observed prim-
ary liver cancer occurrence in humans, namely, 0-g
= 1.7. Table 1 presents, for various percent incre-
ments in the DENA equivalent dose do for back-
ground liver cancer occurrence, the calculated
values of t (median age),p (lifetime probability of
developing cancer), A (average life-span lost by the
entire population). x (the average age of cancer oc-
currence) and 8(the average life-span loss ofcancer
cases).
Table 1. Effect on various response parameters ofthe in-
dicated percentage increments in equivalent carcinogen
dose for liver cancer occurrence in Connecticut males,
1962-64.
Increment
in
equivalent Avg.
carcinogen life span
dose for Avg. loss in Avg.
current age of entire life span
liver Median Proba- cancer popula- loss in
cancer time of bility of occur- tion cancer
experience cancer cancer rence A x 10-2, cases
t,yr pxO-4 x,yr yr S,yr
0 350 18.9 71.27 2.12 11.21
2 347 20.0 71.20 2.25 11.24
5 342 21.7 71.07 2.51 11.32
10 334 24.6 70.87 2.92 11.43
To understand the significance of these figures
let us examine, for example, the effects of the 10%
increase in the equivalent carcinogen dose, i.e., 0.2
,ug/kg-day. This carcinogen exposure reduces the
time of tumor occurrence by 4.8%. The effects in
the average age of cancer occurrence and the cor-
responding losses in life span are summarized in
Table 2. The average age of the 18.9/104 cases
Table 2. Effect of0.2,ug/kg-day of DENA on the incidence,
average age of tumor occurrence and life-span loss of
spontaneous and new hepatic cancer cases.
Average Loss in
Incidence age, life span,
per 104 yr yr
"Spontaneous" cases
(no DENA) 18.9 71.27
"Spontaneous" cases
(with DENA) 18.9 67.85 3.42
Extra cases 5.7 80.75 1.99
Total cases 24.6 70.87
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reduced by 4.8% from 71.27 yr to 67.85 yr. These
spontaneous cancer cases would therefore lose 3.42
yr of life due to the carcinogen exposure. Further-
more, the incidence rises from 18.9/104 to 24.6/104
with the carcinogen exposure so that there are an
extra 5.7/104 cancer cases. However, the average
age of cancer development for all the cancer cases
which occur in association with the carcinogen ex-
posure (24.6/104) decreases onlyslightly from 71.27
yr at background exposure to 70.87 yr with the car-
cinogen exposure. Since the carcinogen exposure
reduces the average age of the original 18.9/104
cancer cases to 67.85 yr, the 5.7/104 extra cancer
cases must have developed at an average age of
80.75 yr since the overall average age of cancer
development in association with the carcinogen ex-
posure is 70.87 yr.
As a result of the carcinogen exposure and the
consequent foreshortening of the cancer time, the
extra cancer cases die somewhat before other
causes of death instead of somewhat later (in prin-
ciple) so that the actual life shortening is roughly
half the full 4.8% loss in life span of the original
cancer cases. Hence, the average age of death at
80.75 yr represents a 2.4% reduction from what it
would have been without the carcinogen exposure,
i.e., 82.74 yr, and, consequently, the extra cancer
cases suffer a 1.99 yr loss of life due to the car-
cinogen exposure. This is substantially less than
the 3.42 yr lost by the original cancer cases and it
also occurs later in life, so that the major brunt of
the life-shortening is.borne by those cancer cases
who would have gotten their disease without the
additional carcinogen exposure.
REFERENCES
1. Mantel, N., and Bryan, W.R., "Safety" testing of car-
cinogenic agents, J. Nat. Cancer Inst., 27: 455 (1961).
2. Blum, H. F., Carcinogenesis by Ultraviolet Light, Princeton
Univ. Press, Princeton, N. J., 1959.
3. Druckrey, H., Quantitative aspects of chemical car-
cinogenesis. In Potential Carcinogenic Hazards from Drugs,
Evaluation of Risks, Rene Truhaut, Ed., UICC Monograph
Series, Vol. 7, Springer-Verlag, New York, 1967, pp. 60-78.
4. Albert, R. E., and Altshuler, B., Considerations relating to
the formulation of limits for unavoidable population ex-
posure to environment carcinogens. In: Radionuclide Car-
cinogenesis, C. L. Sanders, et al., Eds., AEC Symposium
Series, CONF-720505, NTIS, Springfield, Virginia, June
1973, pp. 233-253.
5. Doll, R., Muir, C., and Waterhouse, J., Eds., Cancer Inci-
dence in Five Continents, Vol. II. International Union
Against Cancer, Geneva, 1970 (Distributor: Springer-Verlag,
Berlin, Heidelberg, New York).
6. Doll, R., Payne P., and Waterhouse, J. Eds. Cancer Inci-
dence in Five Continents. A Technical Report. International
Union Against Cancer, Geneva, 1966 (Distributor: Springer-
Verlag, Berlin, Heidelberg, New York).
Environmental Health Perspectives